Alzheimer’s Progression Slowed by Drug in Major Trial

“Lecanemab reduced the pace of cognitive decline in people with early disease by 27% over 18 months when compared with a placebo, meeting the main goal of the trial, the companies said in a statement. The benefit came with side effects, including brain swelling and bleeding, though severe cases were rare.”

Well, it’s a start….

https://www.bloomberg.com/news/articles/2022-09-27/alzheimer-s-slowed-by-amyloid-lowering-drug-from-eisai-biogen